Viz.ai has partnered with Alnylam Pharmaceuticals to accelerate earlier identification and standardize the diagnosis of cardiac amyloidosis, a serious and underdiagnosed cause of heart failure.[1][2] This AI Care Pathway for cardiac amyloidosis uses the FDA-approved Us2.ai algorithm to analyze standard echocardiograms, identify patients with suspicious symptoms, and coordinate confirmatory testing, referrals, and follow-up across teams of cardiologists and heart failure specialists.[1][2] The solution integrates connectivity with electronic health records and generative AI to automate clinical steps according to guidelines.[1] The collaboration includes a multi-site pilot study that evaluates integration into clinical workflows and generates real-world evidence of impact on suspicion, diagnosis, time to treatment, and care coordination.[1][2] The pilot will start on five healthcare systems this year with the aim of wider adoption in the Viz.ai network.[2] ATTR-CM cardiac amyloidosis affects an estimated 350,000 people worldwide, with approximately 80% remaining undiagnosed.[2] Viz Cardio Suite is deployed in 2,000 US hospitals and supports patient care every five seconds.[1]